{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:15:43Z","timestamp":1775301343966,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Global Services, LLC"},{"name":"Millennium Pharmaceuticals, Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Studies have shown that bortezomib retreatment is effective in relapsed\/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE\n                      <jats:sup>\u00ae<\/jats:sup>\n                      OBservational Study (eVOBS) study assessed bortezomib\u2010based therapies for patients with MM in everyday practice. Here, we report on those patients receiving retreatment with bortezomib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consenting adults scheduled to receive bortezomib for MM were enrolled at 162 sites across Europe, Canada, Brazil, Russia, and Turkey between 2006 and 2010. Retrospective data on prior therapies and prospective observational data after bortezomib initiation were captured electronically at baseline, after every bortezomib cycle, and every 12\u00a0weeks after discontinuation or progression. Investigator\u2010assessed responses and adverse events (AEs) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety\u2010six of 873 patients enrolled to eVOBS received bortezomib as first retreatment for progressive disease during the prospective observation period. Median age was 62\u00a0years, 53% were male, and median number of prior therapies at retreatment was 4. Overall, 41% of patients initiated bortezomib retreatment in combination with dexamethasone, 16% in combination with lenalidomide, and 21% received monotherapy. Rate of partial response or better (\u2265PR) was 75% at initial bortezomib therapy, including 44% complete response (CR)\/near CR (nCR); at retreatment, \u2265PR rate was 46%, including 15% CR\/nCR. Median progression\u2010free survival was 11.4\u00a0months (95% confidence interval [CI]: 9.1\u201012.7) from start of initial bortezomib treatment and 6.4\u00a0months (95% CI: 4.4\u20107.2) from start of retreatment. Median overall survival from start of retreatment was 17.6\u00a0months (95% CI: 14.4\u201023.5). Of the 96 patients retreated with bortezomib, 77% reported an AE. Peripheral neuropathy during bortezomib retreatment occurred in 49% of patients, including 10% grade 3\/4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data suggest that retreatment with bortezomib is a feasible option for patients with relapsed\/refractory MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.104","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T12:47:22Z","timestamp":1544186842000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bortezomib retreatment for relapsed and refractory multiple myeloma in real\u2010world clinical practice"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-5161","authenticated-orcid":false,"given":"Cyrille","family":"Hulin","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie H\u00f4pital Haut\u2010L\u00e9v\u00eaque CHU Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Dr Peset Universidad Cat\u00f3lica de Valencia Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens School of Medicine Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens School of Medicine Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Theagenion Cancer Centre Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Santa Casa de S\u00e3o Paulo Medical School S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadewijch","family":"De Samblanx","sequence":"additional","affiliation":[{"name":"Hematology, St Dimpna Hospital Geel Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Marie","family":"Stoppa","sequence":"additional","affiliation":[{"name":"D\u00e9partement D'Onco\u2010H\u00e9matologie Institut Paoli\u2010Calmettes Marseilles France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Aagesen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ryhov County Hospital J\u00f6nk\u00f6ping Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Sargin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine Istanbul University Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Sioni","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens School of Medicine Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"Department of Oncology Cross Cancer Institute Edmonton AB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Division of Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Olie","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag AG Zug Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Don","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Global Services Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Potamianou","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Pharmaceutical SACI Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys215"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.575060"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq370"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.310"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084376"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"issue":"7","key":"e_1_2_10_9_1","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone","volume":"91","author":"Jagannath S","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07359.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07409.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21740"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902912460"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0856-x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0943-z"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1217-0"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517276"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-521468"},{"key":"e_1_2_10_22_1","volume-title":"European Public Assessment Report: Summary for the Public","author":"European Medicines Agency","year":"2013"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.016"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322866"},{"key":"e_1_2_10_26_1","first-page":"A0649","article-title":"Response to re\u2010treatment on relapse multiple myeloma patients previously treated with bortezomib","volume":"93","author":"Rubio\u2010Martinez A","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"w13562","DOI":"10.4414\/smw.2012.13562","article-title":"Effective response with bortezomib retreatment in relapsed multiple myeloma\u2014a multicentre retrospective survey in Switzerland","volume":"142","author":"Taverna C","year":"2012","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"e_1_2_10_28_1","first-page":"755","article-title":"Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series","volume":"6","author":"Wolf J","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"e_1_2_10_29_1","first-page":"309","article-title":"The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed\/refractory multiple myeloma","volume":"34","author":"Lu J","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2014.1496"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845414Y.0000000218"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/145843"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12198"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21517"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.03.005"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12937"},{"key":"e_1_2_10_37_1","unstructured":"Millennium Pharmaceuticals Inc.VELCADE\u00ae (bortezomib) for Injection (For subcutaneous or intravenous use). Prescribing information (revision 18).http:\/\/www.velcade.com\/files\/pdfs\/velcade_prescribing_information.pdf[Internet];2015."},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13147"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"e_1_2_10_41_1","unstructured":"International Myeloma Foundation.Concise review of the disease and treatment options 2011\/2012.;(Available here:http:\/\/myeloma.org\/pdfs\/CR2011\u2010Eng_b1.pdf[Internet]; Accessed in November 2015."},{"key":"e_1_2_10_42_1","first-page":"A260","article-title":"Feasibility and efficacy of bortezomib retreatment in multiple myeloma","volume":"92","author":"Ciolli S","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12805"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood.V124.21.722.722","article-title":"Interim analysis of the Mmrf Commpass trial: identification of novel rearrangements potentially associated with disease initiation and progression","volume":"124","author":"Lonial S","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","unstructured":"NecampJ HaqueS GirniusSK.Practice patterns in newly diagnosed multiple myeloma in the prospective observational Commpass trialAbstract 4502.2016 [Internet];http:\/\/www.myelomabeacon.com\/resources\/mtgs\/ash2016\/abs\/4502\u20102\/.","DOI":"10.1182\/blood.V128.22.4502.4502"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07573.x"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhsr2.104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:24:00Z","timestamp":1775298240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1002\/hsr2.104"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.104","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]},"assertion":[{"value":"2017-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e104"}}